76 results
8-K
EX-99.1
RNLX
Renalytix Plc
28 May 24
Departure of Directors or Certain Officers
7:15am
in chronic disease – FDA approval, broad reimbursement, outcomes data and clinical guidelines. We are incredibly grateful to O. James Sterling for his
424B5
RNLX
Renalytix Plc
15 May 24
Prospectus supplement for primary offering
10:09am
additional financing;
our ability to continue as a going concern;
third-party payor reimbursement and coverage decisions;
the performance of our … be compromised if we do not obtain and maintain coverage and adequate reimbursement from third-party payors—Medicare, specifically—for KidneyIntelX.
Payors from
8-K
EX-1.1
ra27hni4f8p 75i
15 May 24
Entry into a Material Definitive Agreement
9:23am
8-K
EX-99.1
6pt 6rdmosdauvit
15 May 24
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
7:00am
424B3
9bg18nh 5p
7 May 24
Prospectus supplement
6:29pm
8-K
EX-10.2
n2lfkt6r wady
23 Apr 24
Entry into a Material Definitive Agreement
5:00pm
424B5
trtsu49k6j
9 Apr 24
Prospectus supplement for primary offering
4:31pm
8-K
EX-10.1
fos 3twdc9h1xd8
13 Mar 24
Entry into a Material Definitive Agreement
7:00am
8-K
c1ph3gpz
29 Feb 24
Regulation FD Disclosure
6:05am
8-K
EX-99.1
fharkqsizy346n20yo
15 Feb 24
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
7:00am
8-K
EX-99.1
gtz34nnh
17 Jan 24
Update on kidneyIntelX.dkd Local Coverage Determination Consideration
7:15am
8-K
EX-99.1
xuv0 ko9ak7zsl8b5vm
10 Jan 24
Regulation FD Disclosure
7:15am
8-K
EX-99.1
echjsi wg
14 Nov 23
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
12:00am
10-Q
kpsil
14 Nov 23
Quarterly report
12:00am